Colleen Cuffaro is a partner on Canaan’s healthcare investment team. She serves on the boards of Arrakis Therapeutics, Comet Therapeutics, RADD Pharmaceuticals and the New England Venture Capital Association. She also serves as a board observer at RallyBio and Antiva Biosciences. Previously she was a board observer at Spyryx Biosciences, NextCure (NXTC), Arvinas (ARVN) and Novira Therapeutics, which was acquired by Johnson & Johnson. Prior to joining Canaan in 2014, Colleen was an analytical chemist at PMRS, Inc., where she worked with small and large pharmaceutical companies on drug product development, ranging from preclinical feasibility studies to commercial supply. She also served as a bioscience analyst for Entrepreneurship Lab NYC, an accelerator program for healthcare startups. Colleen holds a PhD in cellular and molecular physiology from Yale University and a BA in chemistry from the University of Pennsylvania.